Aerie Pharmaceuticals, Inc. (AERI) News
Filter AERI News Items
AERI News Results
|Loading, please wait...|
AERI News Highlights
- AERI's 30 day story count now stands at 10.
- Over the past 27 days, the trend for AERI's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- ALC, EYE and NOV are the most mentioned tickers in articles about AERI.
Latest AERI News From Around the Web
Below are the latest news stories about AERIE PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AERI as an investment opportunity.
Durham loses public company HQ with Alcon-Aerie deal complete
Former executives at Aerie Pharmaceuticals are in line for major payouts totaling millions of dollars now that the merger with Alcon is complete.
Alcon Completes Acquisition of Aerie Pharmaceuticals, Strengthening Company’s Ophthalmic Pharmaceutical Business
Leveraging Alcon’s robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Alcon’s presence in the $20 billion global ophthalmic pharmaceutical category1 Alcon, the global leader in eye care dedicated to helping people see brilliantly, announced […] The post Alcon Completes Acquisition of Aerie Pharmaceuticals, Strengthening Company’s Ophthalmic Pharmaceutical Business appeared first on AiThority .
Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business
GENEVA, November 22, 2022--Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business
Aerie Pharmaceuticals last day of trading expected Nov. 18 as part of Alcon merger
Aerie Pharmaceuticals'' (AERI) likely last day of trading on the Nasdaq will be on Nov. 18 as part of its merger with Alcon (ALC).
Needham Remains a Hold on Aerie Pharma (AERI)
Needham analyst Serge Belanger maintained a Hold rating on Aerie Pharma (AERI - Research Report) today. The company's shares opened today at $15.21.Belanger covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Cytokinetics, and Aerie Pharma. According to TipRanks, Belanger has an average return of -5.0% and a 37.76% success rate on recommended stocks. Currently, the analyst consensus on Aerie Pharma is a Hold with an average price target of $15.25.See Insiders’ Hot Stocks on TipRanks >> Based on Aerie Pharma's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $33.31 million and a GAAP net loss of $19.37 million.
Aerie Pharmaceuticals Non-GAAP EPS of -$0.27 beats by $0.16, revenue of $36.1M beats by $0.8M
Aerie Pharmaceuticals press release (AERI): Q3 Non-GAAP EPS of -$0.27 beats by $0.16.Revenue of $36.1M (+23.2% Y/Y) beats by $0.8M.Cash, cash equivalents, and investments were…
Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today reports financial results for the third quarter ended September 30, 2022. “Aerie delivered another solid performance in the third quarter and executed well across our three strategic pillars of growth. Our first-in-class
Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates
Aerie (AERI) delivered earnings and revenue surprises of 35.71% and 2.91%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Co-Chairs from Aerie Pharmaceuticals & Santen Inc USA Invite Industry Experts to join Ophthalmic Drugs
The 5th Annual Ophthalmic Drugs Conference will take place in London at the Copthorne Tara Hotel on 21 and 22 November 2022. This event is less than four weeks away. The conference will explore advancements in ophthalmic treatments and variety of
The Zacks Analyst Blog Highlights SilverBow Resources, Amalgamated Financial, PHX Minerals, Richardson Electronics and Aerie Pharmaceuticals
SilverBow Resources, Amalgamated Financial, PHX Minerals, Richardson Electronics and Aerie Pharmaceuticals are part of The Zacks top Analyst Blog.